Prophylactic IL-12 treatment reduces postoperative metastasis: Mediation by increased numbers but not cytotoxicity of NK cells

Breast Cancer Research and Treatment

Volumn 107, Issue 2, 2008, Pages 211-223

  Schwartz, Yossi ^a   Avraham, Roi ^a   Benish, Marganit ^a   Rosenne, Ella ^a   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Active immunotherapy; Cellular immunity; Cytokines; IL 12; Surgery

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LAPAROTOMY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NONHUMAN; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RAT; TUMOR CELL;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ORCIPRENALINE; RATS; RATS, INBRED F344;

EID: 37249068524     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9540-9     Document Type: Article

References (67)

1. Brunda MJ, Luistro L, Warrier RR et al (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230
2. Boggio K, Di Carlo E, Rovero S et al (2000) Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60:359-364
3. Smyth MJ, Taniguchi M, Street SE (2000) The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165:2665-2670
4. Kobayashi T, Shiiba K, Satoh M et al (2002) Interleukin-12 administration is more effective for preventing metastasis than for inhibiting primary established tumors in a murine model of spontaneous hepatic metastasis. Surg Today 32:236-242
5. Zou JP, Yamamoto N, Fujii T et al (1995) Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 7:1135-1145
6. Nastala CL, Edington HD, McKinney TG et al (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153:1697-1706
7. Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155-168
8. Caminschi I, Venetsanakos E, Leong CC et al (1998) Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 19:738-746
9. Cui J, Shin T, Kawano T et al (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623-1626
10. Hurteau JA, Blessing JA, DeCesare SL et al (2001) Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 82:7-10
11. Atkins MB, Robertson MJ, Gordon M et al (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409-417
12. Portielje JE, Kruit WH, Schuler M et al (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5:3983-3989
13. Leonard JP, Sherman ML, Fisher GL et al (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541-2548
14. Rook AH, Wood GS, Yoo EK et al (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902-908
15. Shakhar G, Ben-Eliyahu S (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10:972-992
16. Brittenden J (1996) Natural killer cells and cancer. Cancer 77:1226-1243
17. Ben-Eliyahu S, Page GG, Yirmiya R et al (1999) Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 80:880-888
18. Dithmar SA, Rusciano DA, Armstrong CA et al (1999) Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res 19:426-431
19. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293-299
20. Taketomi A, Shimada M, Shirabe K et al (1998) Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83:58-63
21. Schantz SP, Brown BW, Lira E et al (1987) Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 25:141-148
22. Ben-Eliyahu S, Page GG, Yirmiya R et al (1996) Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 2:457-460
23. Ben-Eliyahu S, Page GG (1992) In vivo assessment of natural killer cell activity in rats. Prog Neuroendocrinemmunol 5:199-214
24. Barlozzari T, Leonhardt J, Wiltrout RH et al (1985) Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 134:2783-2789
25. Shakhar G, Ben-Eliyahu S (1998) In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 160:3251-3258
26. Ben-Eliyahu S, Yirmiya R, Liebeskind JC et al (1991) Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav Immun 5:193-205
27. Melamed R, Rosenne E, Shakhar K et al (2005) Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 19:114-126
28. Barlozzari T, Reynolds CW, Herberman RB (1983) In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol 131:1024-1027
29. Bar-Yosef S, Melamed R, Page GG et al (2001) Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 94:1066-1073
30. Dengler HG, Hengstmann JH (1976) Metabolism and pharmacokinetics of orciprenaline in various animal species and man. Arch Int Pharmacodyn Ther 223:71-87
31. Zuckerman L, Rimmerman N, Weiner I (2003) Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia. Psychopharmacology (Berl) 169:298-307
32. dim subpopulations of rat natural killer cells. J Immunol 148:3658-3665
33. Chambers WH, Vujanovic NL, DeLeo AB et al (1989) Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 169:1373-1389
34. Page GG, Ben-Eliyahu S, Liebeskind JC (1994) The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 8:241-250
35. Ben-Eliyahu S, Page GG, Shakhar G et al (1996) Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: possible role of oestradiol and natural killer cells. Br J Cancer 74:1900-1907
36. Fishkin RJ, Winslow JT (1997) Endotoxin-induced reduction of social investigation by mice: interaction with amphetamine and anti-inflammatory drugs. Psychopharmacology (Berl). 132:335-341
37. Yirmiya R, Tio DL, Taylor AN (1996) Effects of fetal alcohol exposure on fever, sickness behavior, and pituitary-adrenal activation induced by interleukin-1 beta in young adult rats. Brain Behav Immun 10:205-220
38. Yirmiya R, Pollak Y, Morag M et al (2000) Illness, cytokines, and depression. Ann NY Acad Sci 917:478-487
39. Katafuchi T, Kondo T, Yasaka T et al (2003) Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience 120:837-845
40. Ben-Eliyahu S, Shakhar G, Page GG et al (2000) Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 8:154-164
41. Kanaoka E, Takahashi K, Yoshikawa T et al (2002) A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J Control Release 82:183-187
42. Kedar E, Braun E, Rutkowski Y et al (1994) Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J Immunother Emphasis Tumor Immunol 16:115-124
43. Liu L, Sakaguchi T, Kanda T et al (2003) Delivery of interleukin-12 in gelatin hydrogels effectively suppresses development of transplanted colonal carcinoma in mice. Cancer Chemother Pharmacol 51:53-57
44. Gately MK, Desai BB, Wolitzky AG et al (1991) Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874-882
45. Robertson MJ, Soiffer RJ, Wolf SF et al (1992) Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175:779-788
46. Eng VM, Car BD, Schnyder B et al (1995) The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo. J Exp Med 181:1893-1898
47. Gately MK, Warrier RR, Honasoge S et al (1994) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 6:157-167
48. Matsumoto G, Omi Y, Lee U et al (2000) Adhesion mediated by LFA-1 is required for efficient IL-12-induced NK and NKT cell cytotoxicity. Eur J Immunol 30:3723-3731
49. Kawamura T, Takeda K, Mendiratta SK et al (1998) Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 160:16-19
50. Lasek W, Golab J, Maslinski W et al (1999) Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Eur Cytokine Netw 10:345-356
51. Okuno K, Jinnai H, Lee YS et al (1996) Interleukin 12 augments the liver-associated immunity and reduces liver metastases. Hepatogastroenterology 43:1196-1202
52. Gan X, Zhang L, Solomon GF et al (2002) Mechanism of norepinephrine- mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity. Brain Behav Immun 16:227-246
53. Mitsuhashi M, Liu J, Cao S et al (2004) Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol 76:322-332
54. Panina-Bordignon P, Mazzeo D, Lucia PD et al (1997) Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 100:1513-1519
55. Pockaj BA, Basu GD, Pathangey LB et al (2004) Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 11:328-339
56. Ben-Eliyahu S (2003) The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 17:27-36
57. Dithmar S, Rusciano D, Lynn MJ et al (2000) Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol 118:1085-1089
58. Gallagher WJ, Dubinett SM, Hoover HC Jr et al (1989) Efficacy of adjuvant interleukin-2 after excision of BALB/c fibrosarcomas. Surgery 106:120-125
59. Mu J, Zou JP, Yamamoto N et al (1995) Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 55:4404-4408
60. Strohlein MA, Grutzner KU, Schildberg FW et al (2002) Induction of cytotoxicity against autologous tumour cells by interleukin-12: evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients. Cancer Immunol Immunother 51:505-512
61. Brivio F, Lissoni P, Alderi G et al (1996) Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology 53:263-268
62. Brivio F, Lissoni P, Fumagalli L et al (1999) Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer. Oncol Rep 6:1205-1207
63. Deehan DJ, Heys SD, Ashby J et al (1995) Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Surg Oncol 21:16-22
64. Luksch R, Perotti D, Cefalo G et al (2003) Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 89:263-268
65. Coughlin CM, Salhany KE, Gee MS et al (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25-34
66. Dias S, Boyd R, Balkwill F (1998) IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 78:361-365
67. Voest EE, Kenyon BM, O'Reilly MS et al (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586